Abstract
In 2002, Lauren Black had grown frustrated with her job. She had been working at the US Food and Drug Administration as a reviewer for just over a decade. “I saw too many resources wasted,” she says. Drug companies were submitting a surplus of animal studies along with excessive or simply irrelevant data. “I thought it was time to go out and work further upstream.” So she took a job at Charles River Laboratories, a contract research organization (CRO) that drug companies turn to for animal models, toxicology studies, and more. In her 17 years there, Black has helped streamline research and package it into digestible forms for FDA review. And today, she’s taking that thinning to its most extreme form by leading the company’s role in developing N-of-1 therapies—drugs that are custom designed for a single individual’s exceedingly rare genetic mutation. Although Charles River has been involved with only
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.